Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus DESONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus DESONATE.
COR-OTICIN vs DESONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
1-2 drops in each affected ear twice daily for 7 days.
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%).
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid